Moving forward toward a cure for Hemophilia B

Molecular Therapy

Volumn 23, Issue 5, 2015, Pages 809-811

  Vandendriessche, Thierry ^a,b   Chuah, Marinee K ^a,b  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALIPOGENE TIPARVOVEC; FIX PROTEIN; GENE THERAPY AGENT; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR 9;

BLEEDING; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; HEMOPHILIA B; HUMAN; HYPERTRANSAMINASEMIA; LIVER TOXICITY; NONHUMAN; NOTE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ADMINISTRATION AND DOSAGE; GENE THERAPY; GENE VECTOR; GENETICS; MALE;

FACTOR IX; GENETIC THERAPY; GENETIC VECTORS; HEMOPHILIA B; HUMANS; MALE;

EID: 84928941712     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.56     Document Type: Note

References (28)

1. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, et al. (2008). Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 358: 2231-2239
2. Maguire AM, High KA, Auricchio A, Wright JF, Pierce EA, Testa F, et al. (2009). Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 374: 1597-1605; erratum Lancet 2010;375: 30
3. Simonelli F, Maguire AM, Testa F, Pierce EA, Mingozzi F, Bennicelli JL, et al. (2010). Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 18: 643-650
4. Carpentier AC, Frisch F, Labbé SM, Gagnon R, De Wal J, Greentree S, et al. (2012). Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J Clin Endocrinol Metab 97: 1635-1644
5. Gaudet D, Méthot J, Déry S, Brisson D, Essiembre C, Tremblay G, et al. (2013). Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an openlabel trial. Gene Ther 20: 361-369
6. European Medicines Agency. Glybera (public assessment report). http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002145/human-med-001480.jsp&mid=WC0b01ac058001d124
7. Herzog RW, Hagstrom JN, Kung SH, Tai SJ, Wilson JM, Fisher KJ, et al. (1997). Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci USA 94: 5804-5809
8. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, et al. (2006). Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med 12: 342-347
9. Mingozzi F, Maus MV, Hui DJ, Sabatino DE, Murphy SL, Rasko JE, et al. (2007). CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 13: 419-422
10. Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A, et al. (2000). Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 24: 257-261
11. Buchlis G, Podsakoff GM, Radu A, Hawk SM, Flake AW, Mingozzi F, et al. (2012). Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Blood 119: 3038-3041
12. Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J, et al. (2014). Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 371: 1994-2004
13. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, et al. (2011). Adenovirus- associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365: 2357-2365
14. Nathwani AC, Gray JT, McIntosh J, Ng, CY, Zhou J, Spence Y, et al. (2007). Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood 109: 1414-1421
15. World Federation of Hemophilia. Severity of hemophilia http://www.wfh.org/en/page.aspx?pid=643
16. Mingozzi F, Meulenberg JJ, Hui DJ, Basner-Tschakarjan E, Hasbrouck NC, Edmonson SA, et al. (2009). AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood 114: 2077-2086
17. Cantore A, Nair N, Della Valle P, Di Matteo M, Màtrai J, Sanvito F, et al. (2012). Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice. Blood 120: 4517-4520
18. Nair N, Rincon MY, Evens H, Sarcar S, Dastidar S, Samara-Kuko E, et al. (2014). Computationally designed liver-specific transcriptional modules and hyperactive factor IX improve hepatic gene therapy. Blood 123: 3195-3199
19. Simioni P, Tormene D, Tognin G, Gavasso S, Bulato C, Iacobelli NP, et al. (2009). X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med 361: 1671-1675
20. Finn JD, Nichols TC, Svoronos N, Merricks EP, Bellenger DA, Zhou S, et al. (2012). The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy. Blood 120: 4521-4523
21. Crudele JM, Finn JD, Siner JI, Martin NB, Niemeyer GP, Zhou S, et al. (2015). AAV liver expression of FIXPadua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice. Blood 125: 1553-1561
22. Cantore A, Ranzani M, Bartholomae CC, Volpin M, Valle PD, Sanvito F, et al. Liver-directed lentiviral gene therapy in a dog model of hemophilia B. Sci Transl Med. 4;7:277ra28
23. Baxter Healthcare Corporation. Baxter provides progress update on gene therapy program including phase I/II clinical trial of BAX 335, investigational gene therapy for hemophilia B Press release 12 February 2015 http://www.baxter.com/press-room/press-releases/2015/02-12-15-bax355.html
24. Chuah MK, Petrus I, De Bleser P, Le Guiner C, Gernoux G, Adjali O, et al. (2014). Liver-specific transcriptional modules identified by genome-wide in silico analysis enable efficient gene therapy in mice and nonhuman primates. Mol Ther 22: 1605-1613
25. Di Matteo M, Samara-Kuko E, Ward NJ, Waddington SN, McVey JH, Chuah MK, et al. (2014). Hyperactive piggyBac transposons for sustained and robust liver-targeted gene therapy. Mol Ther 22: 1614-1624
26. Lisowski L, Dane AP, Chu K, Zhang Y, Cunningham SC, Wilson EM, et al. (2014). Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature 506: 382-386
27. Martino AT, Suzuki M, Markusic DM, Zolotukhin I, Ryals RC, Moghimi B, et al. (2011). The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood 117: 6459-6468
28. Martino AT, Basner-Tschakarjan E, Markusic DM, Finn JD, Hinderer C, Zhou S, et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121: 2224-2233